CIViC Evidence Items

4766 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline

BClinical — prospective trial or retrospective cohort study

CCase study — single case report or small case series

DPreclinical — in vitro or animal model data

EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

	Predictive	Diagnostic	Prognostic	Functional	Predispos.	Oncogenic
BCR::ABL1	323	11
BRAF	186	4	26	2		1
EGFR	248		12	3		2
EML4::ALK	64
ERBB2	142		2
FLT3	55	2	21
KIT	102	3	7
KRAS	159	4	24			4
PIK3CA	156		16	4
PTEN	53	1	3	1	2	1
TP53	52		40	100	2
VHL	5	2	3		635	15

Predictive:Links a variant to treatment response or resistance

Diagnostic:Supports or refutes a specific disease diagnosis

Prognostic:Informs disease progression or clinical outcome

Functional:Characterises the biological effect of a variant

Predisposing:Germline variant associated with cancer predisposition

Oncogenic:Characterises the variant's role in oncogenesis

Level	Gene	Variant	Type	Direction	Significance	Disease	Drugs	Source
B	WWTR1::CAMTA1	Fusion	Diagnostic	Supports	Positive	Malignant Epithelioid Hemangioendothelioma		Tanas et al., 2011
B	WWTR1::CAMTA1	Fusion	Diagnostic	Supports	Positive	Malignant Epithelioid Hemangioendothelioma		Flucke et al., 2014
B	TP53	Mutation	Predictive	Supports	Sensitivity/Response	Myelodysplastic Syndrome	Azacitidine,Eprenetapopt	Sallman et al., 2021
B	v::NR4A3	Fusion	Diagnostic	Supports	Positive	Acinic Cell Carcinoma		Haller et al., 2019
B	KMT2C	Mutation OR KMT2A Mutation	Predictive	Supports	Sensitivity/Response	Cancer	Immunotherapy	Zhang et al., 2020
B	TMB	High	Predictive	Supports	Sensitivity/Response	Colorectal Cancer	Durvalumab,Tremelimumab	Loree et al., 2024
B	BCR::ABL1	Fusion	Diagnostic	Supports	Positive	Acute Myeloid Leukemia With BCR-ABL1		Soupir et al., 2007
B	BCR::ABL1	Fusion	Diagnostic	Supports	Positive	Acute Myeloid Leukemia With BCR-ABL1		Cuneo et al., 1996
B	BCR::ABL1	Fusion	Diagnostic	Supports	Positive	Acute Myeloid Leukemia With BCR-ABL1		Grimwade et al., 2010
B	BRD4::NUTM1	Fusion	Diagnostic	Supports	Positive	NUT Midline Carcinoma		Lemelle et al., 2017
B	v::NUTM1	Fusion	Diagnostic	Supports	Positive	NUT Midline Carcinoma		Chau et al., 2020
B	v::NUTM1	Fusion	Diagnostic	Supports	Positive	NUT Midline Carcinoma		French et al., 2004
A	v::RET	Fusion OR RET Mutation	Predictive	Supports	Sensitivity/Response	Solid Tumor	Selpercatinib	PMID 231047
B	FUS::CREB3L2	Fusion	Diagnostic	Supports	Positive	Low-grade Fibromyxoid Sarcoma		Guillou et al., 2007
A	KRAS	G12C	Predictive	Supports	Sensitivity/Response	Colorectal Cancer	Cetuximab,Adagrasib	Yaeger et al., 2024
B	v::NTRK1	Fusion OR v::NTRK3 Fusion OR v::NTRK2 Fusion	Predictive	Supports	Sensitivity/Response	Solid Tumor	Entrectinib	Desai et al., 2022
B	MN1	Rearrangement	Diagnostic	Supports	Positive	Astroblastoma, MN1-altered		Lehman et al., 2019
B	MN1	Rearrangement	Prognostic	Supports	Better Outcome	Astroblastoma, MN1-altered		Lehman et al., 2019
B	TMB	High	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Pembrolizumab	Rizvi et al., 2015
B	BCR::ABL1	Fusion	Diagnostic	Supports	Positive	B-lymphoblastic Leukemia/lymphoma With BCR-ABL1		Uckun et al., 1999
B	BCR::ABL1	Fusion	Diagnostic	Supports	Positive	B-lymphoblastic Leukemia/lymphoma With BCR-ABL1		Fletcher et al., 1991
B	BCR::ABL1	Fusion	Diagnostic	Supports	Positive	B-lymphoblastic Leukemia/lymphoma With BCR-ABL1		Brady et al., 2022
B	SS18::SSX1	Fusion	Diagnostic	Supports	Positive	Synovial Sarcoma		Amary et al., 2007
B	DEK::NUP214	Fusion	Diagnostic	Supports	Positive	Acute Myeloid Leukemia With T(6;9) (p23;q34.1)		Slovak et al., 2006
B	DEK::NUP214	Fusion	Diagnostic	Supports	Positive	Acute Myeloid Leukemia With T(6;9) (p23;q34.1)		Tarlock et al., 2014
B	DEK::NUP214	Fusion	Diagnostic	Supports	Positive	Acute Myeloid Leukemia With T(6;9) (p23;q34.1)		Sandahl et al., 2014
C	NPM1::MLF1	Fusion	Diagnostic	Supports	Positive	Acute Myeloid Leukemia With NPM1::MLF1 Fusion		Umeda et al., 2024
B	NPM1::MLF1	Fusion	Diagnostic	Supports	Positive	Acute Myeloid Leukemia With NPM1::MLF1 Fusion		Grimwade et al., 2010
A	EGFR	L858R OR EGFR Exon 19 Deletion	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Amivantamab,Lazertinib	Felip et al., 2024
C	GOPC::ROS1	Fusion	Predictive	Supports	Sensitivity/Response	Melanoma	Entrectinib	Drilon et al., 2017
B	TOP1	Amplification	Predictive	Supports	Sensitivity/Response	Colorectal Cancer	Cetuximab,FOLFIRI Regimen	Ohnmacht et al., 2023
B	KAT6A::CREBBP	Fusion	Diagnostic	Supports	Positive	AML With KAT6A::CREBBP Fusion		Coenen et al., 2013
A	EGFR	L858R OR EGFR Exon 19 Deletion	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Pemetrexed,Carboplatin,Amivantamab	Passaro et al., 2024
A	RET	Mutation	Predictive	Supports	Sensitivity/Response	Medullary Thyroid Carcinoma	Selpercatinib	Hadoux et al., 2023
A	BRAF	V600E	Predictive	Supports	Sensitivity/Response	Solid Tumor	Trametinib,Dabrafenib	Subbiah et al., 2023
A	BRAF	V600E	Predictive	Supports	Sensitivity/Response	Low Grade Glioma	Dabrafenib,Trametinib	Bouffet et al., 2023
C	TCF3::HLF	Fusion	Diagnostic	Supports	Positive	B-lymphoblastic Leukemia/lymphoma With TCF3::HLF Fusion		Fischer et al., 2015
B	CEBPA	Mutation	Diagnostic	Supports	Positive	Acute Myeloid Leukemia With Mutated CEBPA		Taube et al., 2022
B	CEBPA	Mutation	Diagnostic	Supports	Positive	Acute Myeloid Leukemia With Mutated CEBPA		Wakita et al., 2022
B	MEF2D::v	Fusion	Diagnostic	Supports	Positive	B-lymphoblastic Leukemia With MEF2D Rearrangement		Ohki et al., 2019
B	MEF2D::v	Fusion	Diagnostic	Supports	Positive	B-lymphoblastic Leukemia With MEF2D Rearrangement		Gu et al., 2016
C	NUP214::ABL1	Fusion	Predictive	Supports	Sensitivity/Response	B-lymphoblastic Leukemia/lymphoma	Imatinib Mesylate	Stukaite-Ruibiene et al., 2022
B	CEBPA	Mutation	Prognostic	Supports	Better Outcome	Acute Myeloid Leukemia With Mutated CEBPA		Tarlock et al., 2021
B	v::NUTM1	Fusion	Diagnostic	Supports	Positive	B-lymphoblastic Leukemia With NUTM1 Rearrangement		Hormann et al., 2019
B	v::NUTM1	Fusion	Diagnostic	Supports	Positive	B-lymphoblastic Leukemia With NUTM1 Rearrangement		Boer et al., 2021
B	v::NUTM1	Fusion	Diagnostic	Supports	Positive	B-lymphoblastic Leukemia With NUTM1 Rearrangement		Fazio et al., 2021
C	IGH::IL3	Fusion	Diagnostic	Supports	Positive	B-lymphoblastic Leukemia/lymphoma With IGH::IL3 Fusion		Guenzel et al., 2021
A	v::NRG1	Fusion	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Zenocutuzumab-zbco	Schram et al., 2025
A	v::NRG1	Fusion	Predictive	Supports	Sensitivity/Response	Pancreatic Adenocarcinoma	Zenocutuzumab-zbco	Schram et al., 2025
B	IGH::DUX4	Fusion	Diagnostic	Supports	Positive	B-lymphoblastic Leukemia With DUX4 Rearrangement		Yasuda et al., 2016

Page 23 of 96

Previous Next